stockrow
Saturday 7 November 2026
Export CELU’s income statement to Excel — free account
Celularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024.
- Revenue
- −5.30%
- EPS
- +102.0%
- Free cash flow
- −10.9%
- Total debt
- −1.51%
Quarter to June 2026, against a year earlier
0.76
0.03
+4.11%
Follow CELU
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 1 | 1 | 1 |
+8 more TTM periods Free account |
| 151.53% | 349.83% | 628.23% | 5,736.39% | ||
| (42.72%) | (62.45%) | (76.50%) | (66.41%) | ||
ROIC |
(462.77%) | (695.71%) | (1,070.92%) | (153.64%) | |
Return on Tangible Assets |
(49,717.20%) | 734.06% | 726.09% | (3,220.71%) | |
Average Days of Receivables |
91.53 | 91.99 | 63.97 | 60.31 | |
Free Cash Flow per Share |
(0.31) | (0.30) | (0.52) | (0.25) | |
Free Cash Flow |
(8.92) | (8.81) | (13.25) | (6.56) | |
| Other line items | |||||
Cash ROIC |
(113.90%) | (141.89%) | (83.21%) | (32.81%) | |
Accounts Receivable Turnover |
2.36 | 1.92 | 2.92 | 5.24 | |
Accounts Payable Turnover |
0.77 | 0.74 | 0.81 | 1.00 | |
Inventory Turnover |
5.88 | 5.39 | 6.71 | 6.14 | |
Average Days of Payables |
352.92 | 509.77 | 480.42 | 447.75 | |
Days of Inventory on Hand |
17.38 | 9.69 | 10.38 | 46.67 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
69.47% | 75.33% | 56.59% | 38.21% | |
Selling, General and Administrative Expense of Revenue |
206.12% | 243.38% | 193.09% | 128.79% | |
Share Based Compensation of Revenue |
39.54% | 47.36% | 39.09% | 24.81% | |
Interest Coverage |
(16.99) | (13.06) | (9.08) | (6.33) | |
Operating CF/Net income |
0.19 | 0.12 | 0.14 | 0.08 | |
Depreciation/Fixed assets |
0.13 | 0.13 | 0.13 | 0.13 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.64 | 0.65 | 1.04 | 1.54 | |
Operating CF per Share |
(0.31) | (0.30) | (0.52) | (0.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026